Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma

Journal of Physiology and Pharmacology

Volumn 63, Issue 6, 2012, Pages 589-599

  Lekstan, A ^a   Lampe, P ^a   Lewin Kowalik, J ^a   Olakowski, M ^a   Jablonska, B ^a   Labuzek, K ^a   Jedrzejowska Szypulka, H ^a   Olakowska, E ^a   Gorka, D ^a   Filip, I ^a   Dranka Bojarowska, D ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Chronic pancreatitis; Gelatinases; Metalloproteinases; Pancreatic cancer; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INFILTRATION; CANCER INVASION; CHRONIC PANCREATITIS; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84873448907     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis 2010; 28: 645-656.
2. Gabryelewicz A. Choroby nowotworowe przewodu pokarmowego. In: Gastroenterologia w praktyce. A. Gabryelewicz, (ed.) PZWL, 2002, 251-297.
3. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258.
4. Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. (review). Best Pract Res Clin Gastroenterol 2008; 22: 45-63.
5. Lukaszewicz M, Mroczko B, Szmitkowski M. Rola metaloproteinaz i ich inhibitorów w raku trzustki. Postepy Hig Med Dosw 2008; 62: 141-147.
6. Dragun P, Makarewicz D, Wojcik L, Ziemka-Nalecz M, Slomka M, Zalewska T. Matrix metaloproteinases activity during the evolution of hypoxic-ischemic brain damage in the immature rat. The effect of 1-methylnicotinamide (MNA). J Physiol Pharmacol 2008; 59: 441-455.
7. Sokolowska B, Jozwik A, Niebroj-Dobosz I, Janik P, Kwiecinski H. Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern recognition methods. J Physiol Pharmacol 2009; 60(Suppl 5): 117-120.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
9. Bloomston M, Zervos ED, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002; 9: 668-674.
10. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198.
11. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 2005; 106: 127-132.
12. Kotulska-Wolwender K, Larysz-Brysz M, Fus Z, Korczynska I, Gorka D, Lewin-Kowalik J. Metaloproteinazy macierzy pozakomorkowej-perspektywy ich wykorzystania w medycynie. Wiad Lek 2002; 55: 463-471.
13. Woszczynska-Korczynska I, Gorka D, Matuszek I, Pietrucha-Dutczak M, Lewin-Kowalik J. Aktywnosc metaloproteinaz (MMP2, MMP9) w odcinkach dystalnych przecietych nerwow kulszowych doroslych szczurow. Wiad Lek 2005; 58: 411-414.
14. Gross J, Lapiere C. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48: 1014-1022.
15. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in situ localization of genes encoding for extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-413.
16. Satoh K, Ohtani H, Shimosegawa T, Koizumi M, Sawai T, Toyota T. Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology 1994; 107: 1488-1495.
17. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-3455.
18. Rigg AS, Lemoine NS. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 2001; 8: 869-878.
19. Pezzilli R. Etiology of chronic pancreatitis: has it changed in the last decade? World J Gastroenterol 2009; 15: 4737-4740.
20. Otsuki M. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-326.
21. Kimura W. Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 2008; 15: 270-277.
22. Matos JM, Schmidt CM, Turrini O, et al. Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg 2009; 13: 1495-1502.
23. Muller MW, Friess H, Kleeff J, et al. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg 2006; 244: 909-918.
24. Hildebrand P, Dudertadt S, Czymek R, et al. Different surgical strategies for chronic pancreatitis significantly improve long-term outcome: a comparative single center study. Eur J Med Res 2010; 15: 351-356.
25. King JC, Abeywardina S, Farrell JJ, Reber HA, Hines OJ. A modern review of the operative management of chronic pancreatitis. Am Surg 2010; 76: 1071-1074.
26. Russell RC, Theis BA. Pancreatoduodenectomy in the treatment of chronic pancreatitis. World J Surg 2003; 27: 1203-1210.
27. Frey CF, Amikura K. Local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy in the management of patients with chronic pancreatitis. Ann Surg 1994; 220: 492-504.
28. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13: 1337-1344.
29. David M, Lepage C, Jouve JL, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009; 101: 215-218.
30. Badger SA, Brant JL, Jones C, et al. The role of surgery for pancreatic cancer: a 12-year review of patient outcome. Ulster Med J 2010; 79: 70-75.
31. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metaloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci 1999; 880: 288-307.
32. Descamps FJ, Martens E, Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 2002; 82: 1607-1608.
33. Koshiba T, Hosotani R, Wada M, et al. Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today 1997; 27: 302-304.
34. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38: 613-618.
35. Ellenrieder V, Alber B, Lacher U, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20.
36. Yokoyama M, Ochi K, Ichimura M, et al. Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002; 24: 344-347.
37. Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001; 7: 251-259.
38. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8: 241.
39. Giannopoulos G, Pavlakis K, Parasi A, et al. The expression of matrix metalloproteinases-2 and-9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res 2008; 28(3B): 1875-1881.
40. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996; 73: 972-978.
41. Yamaguchi T, Kihara Y, Taguchi M, et al. Persistent destruction of the basement membrane of the pancreatic duct contributes to progressive acinar atrophy in rats with experimentally induced pancreatitis. Pancreas 2005; 31: 365-372.
42. Pryczynicz A, Guzinska-Ustymowicz K, Dymicka-Piekarska V, Czyzewska J, Kemona A. Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 2007; 45: 37-40.
43. Uchima Y, Sawada T, Nishihara T, Maeda K, Ohira M, Hirakawa K. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 2004; 29: 123-131.
44. Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002; 24: 169-178.
45. Harvey SR, Hurd TC, Markus G, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003 Oct; 9: 4935-4943.
46. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metaloproteinases and tissue inhibitors expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004; 10: 2832-2845.
47. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010; 24: 256-261.
48. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Malecka-Panas E. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology 2010; 10: 689-694.
49. Sugumar A, Takahashi N, Chari ST. Distinguishing pancreatic cancer from autoimmune pancreatitis. Curr Gastroenterol Rep 2010; 12: 91-97.
50. van Toorenenbergen AW, van Heerde MJ, van Buuren HR. Potential value of serum total IgE for differentiation between autoimmune pancreatitis and pancreatic cancer. Scand J Immunol 2010; 72: 444-448.
51. Talar-Wojnarowska R, Gasiorowska A, Olakowski M, et al. Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis. J Physiol Pharmacol 2010; 61: 711-716.
52. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15.
53. Filip GA, Postescu ID, Tatomir C, Muresan A, Clichici S. Calluna vulgaris extract modulates NF-κB/ERK signaling pathway and matrix metalloproteinase expression in SKH-1 hairless mice skin exposed to ultraviolet B irradiation. J Physiol Pharmacol 2012; 63: 423-432.